Skip to main content

AstraZeneca and improving asthma control

| News

AstraZeneca and improving asthma control


AstraZeneca and the Basel-based startup are jointly developing a new digital solution to treat chronic respiratory diseases. Studies at University Hospital Zurich and in Israel should lead to a shift from reactive treatment to early intervention.

The pharmaceutical group AstraZeneca is seeking to improve the treatment of respiratory diseases together with the Basel-based startup Founded in 2017, the company focuses on commercializing software as medical device (SaMD) products for digital therapeutics. It is active across the German-speaking DACH (Germany, Austria and Switzerland) region as well as in Israel.

According to a press release, both companies are striving to develop a digital solution that monitors the asthmatic status of sufferers in real time, recognizes potentially critical situations and immediately sends an alert to the medical staff treating the patient. To achieve this, an app combines feedback from the patients with automatically collected real data, which shows, for example, the air quality in their surroundings.

Using a digital solution, the aim is to expand the basis for assessing the state of health of sick people. As the press release explains, at present this is only based on patient reports on the day that they visit the doctor. This could lead to unsuitable medical measures and improper use of inhalers.

Personalized therapies could help to massively improve the quality of life of more than 550 million people around the world affected by such conditions in addition to relieving the strain on healthcare systems, according to Ohad Goldberg, Country President of AstraZeneca Israel, in the press release. “The ambition of this collaboration is to change the future of the treatment of chronic respiratory diseases”, he states.

The partnership will initially involve a clinical study at Israel’s largest hospital, Sheba Hospital in Tel Aviv, before an observational study at University Hospital Zurich follows. The first phase of the study is set to be concluded by the end of September.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.